NVCT · Insider Trading
Nuvectis Pharma, Inc. Common Stock
Every open-market purchase and sale reported by NVCT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Michael J. Carson | Vice President, Finance | A | +30,000 | — |
| 2026-07-01 | Ron Bentsur | Chairman & CEO | Buy | +12,500 | +$250.00K |
| 2026-07-01 | Marlio Charles Mosseri | 10%+ Owner | Buy | +50,000 | +$916.00K |
| 2026-06-12 | Kenneth Hoberman | Director | A | +35,000 | — |
| 2026-06-12 | Matthew L. Kaplan | Director | A | +35,000 | — |
| 2026-06-12 | James F Oliviero III | Director | A | +35,000 | — |
| 2026-06-12 | Juan Sanchez | Director | A | +35,000 | — |
| 2026-01-09 | Michael J. Carson | Vice President, Finance | A | +61,200 | — |
| 2026-01-09 | Shay Shemesh | Chief Dev. & Ops. Officer | A | +150,000 | — |
| 2026-01-09 | Ron Bentsur | Chairman & CEO | A | +150,000 | — |
| 2026-01-09 | Enrique Poradosu | Chief Science & Business Off | A | +150,000 | — |
| 2025-11-06 | Matthew L. Kaplan | Director | Buy | +11,000 | +$64.24K |
| 2025-11-06 | Ron Bentsur | Chairman & CEO | Buy | +5,000 | +$28.60K |
| 2025-11-06 | Juan Sanchez | Director | Buy | +13,000 | +$75.27K |
| 2025-10-31 | Juan Sanchez | Director | A | +30,000 | — |
| 2025-10-29 | Marlio Charles Mosseri | 10%+ Owner | Buy | +154,770 | +$957.08K |
| 2025-06-24 | Marlio Charles Mosseri | 10%+ Owner | Buy | +5,603 | +$44.77K |
| 2025-06-20 | Marlio Charles Mosseri | 10%+ Owner | Buy | +33,442 | +$269.53K |
| 2025-06-12 | Kenneth Hoberman | Director | A | +30,000 | — |
| 2025-06-12 | Matthew L. Kaplan | Director | A | +30,000 | — |
| 2025-06-12 | James F Oliviero III | Director | A | +30,000 | — |
| 2025-05-13 | Marlio Charles Mosseri | 10%+ Owner | Buy | +21,167 | +$171.66K |
| 2025-05-12 | Marlio Charles Mosseri | 10%+ Owner | Buy | +27,662 | +$247.26K |
| 2025-05-09 | Marlio Charles Mosseri | 10%+ Owner | Buy | +27,411 | +$235.65K |
| 2025-02-11 | Marlio Charles Mosseri | 10%+ Owner | Buy | +240,000 | +$1.20M |
| 2025-01-03 | Ron Bentsur | Chairman & CEO | A | +250,000 | — |
| 2025-01-03 | Shay Shemesh | Chief Dev. & Ops. Officer | A | +150,000 | — |
| 2025-01-03 | Michael J. Carson | Vice President, Finance | A | +51,000 | — |
| 2025-01-03 | Enrique Poradosu | Chief Science & Business Off | A | +150,000 | — |
| 2024-12-26 | Ron Bentsur | Chairman & CEO | Buy | +4,500 | +$20.93K |
| 2024-12-16 | Marlio Charles Mosseri | 10%+ Owner | Buy | +17,000 | +$79.90K |
| 2024-12-16 | Marlio Charles Mosseri | 10%+ Owner | Buy | +49,121 | +$228.94K |
| 2024-11-20 | Enrique Poradosu | Chief Science & Business Off | Buy | +2,000 | +$9.98K |
| 2024-11-18 | Ron Bentsur | Chairman & CEO | Buy | +20,000 | +$98.40K |
| 2024-11-08 | Michael J. Carson | Vice President, Finance | MIXED | +60,618 | −$22.48K |
| 2024-06-13 | James F Oliviero III | Director | A | +30,000 | — |
| 2024-06-13 | Kenneth Hoberman | Director | A | +30,000 | — |
| 2024-06-13 | Matthew L. Kaplan | Director | A | +30,000 | — |
| 2024-05-15 | Ron Bentsur | Chairman & CEO | Buy | +1,940 | +$13.08K |
| 2024-05-13 | Ron Bentsur | Chairman & CEO | Buy | +2,000 | +$12.80K |
| 2024-05-13 | Enrique Poradosu | Chief Science & Business Off | Buy | +500 | +$3.15K |
| 2024-05-13 | Shay Shemesh | Chief Dev. & Ops. Officer | Buy | +1,113 | +$7.03K |
| 2024-03-19 | Ron Bentsur | Chairman & CEO | Buy | +5,000 | +$51.45K |
| 2024-01-05 | Enrique Poradosu | Chief Science & Business Off | A | +130,000 | — |
| 2024-01-05 | Shay Shemesh | Chief Dev. & Ops. Officer | A | +130,000 | — |
| 2023-10-12 | Ron Bentsur | Chairman & CEO | Buy | +640 | +$7.09K |
| 2023-10-10 | Ron Bentsur | Chairman & CEO | Buy | +1,080 | +$12.11K |
| 2023-10-06 | Ron Bentsur | Chairman & CEO | Buy | +3,220 | +$35.45K |
| 2023-08-16 | Ron Bentsur | Chairman & CEO | Buy | +350 | +$5.11K |
| 2023-08-11 | Ron Bentsur | Chairman & CEO | Buy | +300 | +$4.42K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ron Bentsur | Chairman & CEO | 3,688,424 | $68.20M |
| Marlio Charles Mosseri | 10%+ Owner | 3,295,897 | $60.94M |
| Enrique Poradosu | Chief Science & Business Off | 1,806,319 | $33.40M |
| Shay Shemesh | Chief Dev. & Ops. Officer | 1,793,068 | $33.15M |
| Michael J. Carson | Vice President, Finance | 230,118 | $4.25M |
| Kenneth Hoberman | Director | 168,140 | $3.11M |
| Matthew L. Kaplan | Director | 159,760 | $2.95M |
| James F Oliviero III | Director | 122,828 | $2.27M |
| Juan Sanchez | Director | 113,795 | $2.10M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NVCT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.